TILA-TACE in Treatment of Hepatocellular Carcinoma

Status Recruiting

Clinical Trial Summary

To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate. However, as the study sample size was 40, the investigators need to validate the tumor response rate using a larger sample size; To validate the overall survival: in the previous study, the investigators showed that TILA-TACE significantly prolonged the overall survival of the patients with large and massive tumor. Again, the sample size was small, the investigators need to validate the data using a large sample size.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03910140
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact
Status	Recruiting
Phase	N/A
Start date	November 1, 2017
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04025840` - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery	Phase 4
Completed	`NCT04111926` - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery	Phase 4
Recruiting	`NCT04101760` - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer	Phase 3
Withdrawn	`NCT03342300` - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma	Phase 2/Phase 3
Completed	`NCT03923400` - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn	`NCT02201381` - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer	Phase 3
Recruiting	`NCT05392257` - Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial	Phase 2
Recruiting	`NCT05310357` - Chromosomal Instability in Ovarian Cancer
Recruiting	`NCT05310305` - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting	`NCT05310370` - HRD and Resistance to PAPPi in EOC Patients
Active, not recruiting	`NCT04245644` - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting	`NCT04245410` - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed	`NCT02980185` - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer	N/A
Recruiting	`NCT03967457` - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting	`NCT04050787` - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer	N/A
Recruiting	`NCT03892577` - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Completed	`NCT03726021` - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT02942238` - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)	N/A
Not yet recruiting	`NCT01236989` - Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC	N/A
Recruiting	`NCT05218629` - Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer	Phase 2